Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project

Manuscript Number: 

18-0370R1

Author(s): 
Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Christophe Bintener, Jacoline C. Bouvy, Laura Campo, Carlos Diaz, John Gallacher, Jean Georges, Alastair M. Gray, Antje Hottgenroth, Pall Jonsson, Brent Mittelstadt, Michele H. Potashman, Catherine Reed, Cathie Sudlow, Robin Thompson, Antje Tockhorn-Heidenreich, Andrew Turner, Pieter Jelle Visser, Frederic de Reydet de Vulpillieres, Johan van der Lei

Disclosures

Billy Amzal

  • Patents/Royalties
    Employee of Analytical Laser whose consultancy in the ROADMAP project was funded by Novartis Pharma AG

Zuzanna Angehrn

  • Patents/Royalties
    Employee of Analytical Laser whose consultancy in the ROADMAP project was funded by Novartis Pharma AG

Christin Bexelius

  • Patents/Royalties
    Employee of F. Hoffmann-La Roche

Christophe Bintener

  • Nothing to Disclose

Jacoline C. Bouvy

  • Nothing to Disclose

Laura Campo

  • Sponsors:
    Employee of Eli Lilly and Company

Frederic de Reydet de Vulpillieres

  • Patents/Royalties
    Employee of Novartis

Carlos Diaz

  • Nothing to Disclose

John Gallacher

  • Nothing to Disclose

Jean Georges

  • Nothing to Disclose

Alastair M. Gray

  • Nothing to Disclose

Antje Hottgenroth

  • Sponsors:
    Employee of Eli Lilly and Company

Pall Jonsson

  • Nothing to Disclose

Brent Mittelstadt

  • Nothing to Disclose

Michele H. Potashman

  • Patents/Royalties
    Employee of Biogen

Catherine Reed

  • Equity:
    Minor stockholder of Eli Lilly and Company
    Sponsors:
    Employee of Eli Lilly and Company

Cathie Sudlow

  • Nothing to Disclose

Robin Thompson

  • Patents/Royalties
    Employee of Biogen

Antje Tockhorn-Heidenreich

  • Sponsors:
    Employee of Eli Lilly and Company

Andrew Turner

  • Nothing to Disclose

Johan van der Lei

  • Nothing to Disclose

Pieter Jelle Visser

  • Nothing to Disclose